Sustained virologic response and changes in liver fibrosis parameters following 12-wk administration of generic sofosbuvir and daclatasvir in HIV/HCV-coinfected patients with HCV genotype 4 infection

Abstract Background Novel direct-acting antiviral agents have shown great efficacy and tolerability in HCV-monoinfected patients. However, data are lacking regarding their efficacy and safety in HIV/HCV-genotype (GT) 4-coinfected patients. Methods A single-centre, prospective study including HIV/HCV...

Full description

Saved in:
Bibliographic Details
Published in:Transactions of the Royal Society of Tropical Medicine and Hygiene 2020-04, Vol.114 (4), p.232-240
Main Authors: Cordie, Ahmed, Elsharkawy, Aisha, Abdel Alem, Shereen, Meshaal, Safa, El Akel, Wafaa, Abdellatif, Zeinab, Kamal, Walid, Al Askalany, Mahmoud, Kamel, Sherif, Abdel Aziz, Hossam, Kandeel, Amr, Esmat, Gamal
Format: Article
Language:English
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Background Novel direct-acting antiviral agents have shown great efficacy and tolerability in HCV-monoinfected patients. However, data are lacking regarding their efficacy and safety in HIV/HCV-genotype (GT) 4-coinfected patients. Methods A single-centre, prospective study including HIV/HCV-GT 4-coinfected patients who were treated with sofosbuvir and daclatasvir (SOF/DCV) was conducted for 12 wk. Sustained virological response (SVR) at week 12 post-treatment (SVR12), adverse events (AEs) and changes in liver stiffness measurement (LSM) at SVR12 in comparison with baseline were evaluated. Results SVR12 was achieved in 46 of 50 patients (92%). No significant difference in SVR12 was noticed among patients who received antiretroviral therapy (ART) regimens compared with those who did not receive ART regimens or between those with insignificant fibrosis (
ISSN:0035-9203
1878-3503
DOI:10.1093/trstmh/trz120